X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ADCOCK INGRAM
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
ADCOCK INGRAM
Jun-14
VENUS REMEDIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs143360-   
Low Rs65259-   
Sales per share (Unadj.) Rs324.2107.0-  
Earnings per share (Unadj.) Rs6.4-27.0-  
Cash flow per share (Unadj.) Rs40.6-22.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.084.0-  
Shares outstanding (eoy) m12.34168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 11.1%   
Avg P/E ratio x16.2-11.5 -141.2%  
P/CF ratio (eoy) x2.6-13.9 -18.5%  
Price / Book Value ratio x0.33.7 7.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,28252,238 2.5%   
No. of employees `0000.94.3 21.0%   
Total wages/salary Rs m2513,279 7.7%   
Avg. sales/employee Rs Th4,430.14,205.5 105.3%   
Avg. wages/employee Rs Th278.0763.7 36.4%   
Avg. net profit/employee Rs Th87.6-1,059.7 -8.3%   
INCOME DATA
Net Sales Rs m4,00018,054 22.2%  
Other income Rs m23126 18.0%   
Total revenues Rs m4,02318,181 22.1%   
Gross profit Rs m785-3,129 -25.1%  
Depreciation Rs m422779 54.1%   
Interest Rs m344489 70.3%   
Profit before tax Rs m42-4,271 -1.0%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37267 -13.9%   
Profit after tax Rs m79-4,549 -1.7%  
Gross profit margin %19.6-17.3 -113.2%  
Effective tax rate %-87.9-6.2 1,406.5%   
Net profit margin %2.0-25.2 -7.8%  
BALANCE SHEET DATA
Current assets Rs m2,60613,223 19.7%   
Current liabilities Rs m1,9807,440 26.6%   
Net working cap to sales %15.632.0 48.8%  
Current ratio x1.31.8 74.0%  
Inventory Days Days128111 115.7%  
Debtors Days Days43124 34.8%  
Net fixed assets Rs m5,3537,708 69.5%   
Share capital Rs m12384 147.2%   
"Free" reserves Rs m4,3930-   
Net worth Rs m4,51614,171 31.9%   
Long term debt Rs m1,6184,980 32.5%   
Total assets Rs m8,29126,770 31.0%  
Interest coverage x1.1-7.7 -14.5%   
Debt to equity ratio x0.40.4 102.0%  
Sales to assets ratio x0.50.7 71.5%   
Return on assets %5.1-15.2 -33.6%  
Return on equity %1.8-32.1 -5.5%  
Return on capital %6.3-19.8 -31.8%  
Exports to sales %00-   
Imports to sales %18.40-   
Net fx Rs m-7360-   
CASH FLOW
From Operations Rs m9971,541 64.7%  
From Investments Rs m-461-473 97.5%  
From Financial Activity Rs m-5714,520 -12.6%  
Net Cashflow Rs m-355,587 -0.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.96 Rs / ZAR

Compare VENUS REMEDIES With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: PLETHICO PHARMA  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  SUN PHARMA  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 20, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - ALEMBIC LTD COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS